MRI evaluation of brain iron in earlier- and later-onset Parkinson's disease and normal subjects

Magnetic Resonance Imaging

Volumn 17, Issue 2, 1999, Pages 213-222

  Bartzokis, George ^a,b,c,d   Cummings, Jeffrey L ^c,d   Markham, Charles H ^c   Marmarelis, Panos Z ^c   Treciokas, Leo J ^c   Tishler, Todd A ^b,d   Marder, Stephen R ^c,d   Mintz, Jim ^c  

^a CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Basal ganglia; Ferritin; Field dependent; Iron; Onset; Parkinson's Disease; Substantia nigra

Indexed keywords

FERRITIN; IRON;

ARTICLE; BRAIN LEVEL; CAUDATE NUCLEUS; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC IMAGING; EXTRAPYRAMIDAL SYSTEM; FERRITIN BLOOD LEVEL; FRONTAL LOBE; GLOBUS PALLIDUS; HUMAN; IMAGE ANALYSIS; IRON BLOOD LEVEL; IRON METABOLISM; IRON STORAGE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PRIORITY JOURNAL; PUTAMEN; SUBSTANTIA NIGRA; WHITE MATTER;

EID: 0032895811     PISSN: 0730725X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0730-725X(98)00155-6     Document Type: Article

References (64)

1. Connor J.R., Benkovic S.A. Iron regulation in the brain histochemical, biochemical, and molecular considerations . Ann. Neurol. 32 Suppl:1992;S51-S61.
2. Lan J., Jiang D.H. Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice. J Neural Transm. 104:1997;469-481.
3. Hallgren B., Sourander P. The effect of age on the non-haemin iron in the human brain. J Neurochem. 3:1958;41-51.
4. Earle K.M. Studies on Parkinson's disease including x-ray fluorescent spectroscopy of formalin fixed brain tissue. J Neuropathol Exp Neurol. 27:1968;1-14.
5. Sofic E., Riederer P., Heinsen H., Beckmann H., Reynolds G.P., Hebenstreit G., Youdim M.B. Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Transm. 74:1988;199-205.
6. Jellinger K., Paulus W., Grundke-Iqbal I., Riederer P., Youdim M.B. Brain iron and ferritin in Parkinson's and Alzheimer's diseases. J Neural Transm Park Dis Dement Sect. 2:1990;327-340.
7. Dexter D.T., Carayon A., Javoy-Agid F., Agid Y., Wells F.R., Daniel S.E., Lees A.J., Jenner P., Marsden C.D. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain. 114:1991;1953-1975.
8. Mann V.M., Cooper J.M., Daniel S.E., Srai K., Jenner P., Marsden C.D., Schapira A.H. Complex I, iron, and ferritin in Parkinson's disease substantia nigra. Ann Neurol. 36:1994;876-881.
9. Morris C.M., Edwardson J.A. Iron histochemistry of the substantia nigra in Parkinson's disease. Neurodegeneration. 3:1994;277-282.
10. Hirsch E.C., Brandel J.P., Galle P., Javoy-Agid F., Agid Y. Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease an X-ray microanalysis . J Neurochem. 56:1991;446-451.
11. Sofic E., Paulus W., Jellinger K., Riederer P., Youdim M.B. Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. J Neurochem. 56:1991;978-982.
12. Riederer P., Sofic E., Rausch W.D., Schmidt B., Reynolds G.P., Jellinger K., Youdim M.B. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem. 52:1989;515-520.
13. Loeffler D.A., Connor J.R., Juneau P.L., Snyder B.S., Kanaley L., DeMaggio A.J., Nguyen H., Brickman C.M., LeWitt P.A. Transferrin and iron in normal, Alzheimer's disease, and Parkinson's disease brain regions. J Neurochem. 65:1995;710-717.
14. Chen J.C., Hardy P.A., Kucharczyk W., Clauberg M., Joshi J.G., Vourlas A., Dhar M., Henkelman R.M. MR of human postmortem brain tissue correlative study between T2 and assays of iron and ferritin in Parkinson and Huntington disease . AJNR. 14:1993;275-281.
15. Morris C.M., Candy J.M., Keith A.B., Oakley A.E., Taylor G.A., Pullen R.G., Bloxham C.A., Gocht A., Edwardson J.A. Brain iron homeostasis. J Inorg Biochem. 47:1992;257-265.
16. Hill J.M. The distribution of iron in the brain. Youdim M.B.H. Brain Iron Neurochemical and Behavioural Aspects . 1988;1-24 Taylor & Francis, New York.
17. Connor J.R., Snyder B.S., Arosio P., Loeffler D.A., LeWitt P. A quantitative analysis of isoferritins in select regions of aged, parkinsonian, and Alzheimer's diseased brains. J Neurochem. 65:1995;717-724.
18. Chen J.C., Hardy P.A., Clauberg M., Joshi J.G., Parravano J., Deck J.H., Henkelman R.M., Becker L.E., Kucharczyk W. T2 values in the human brain Comparison with quantitative assays of iron and ferritin . Radiology. 173:1989;521-526.
19. Drayer B., Burger P., Darwin R., Riederer S., Herfkens R., Johnson G.A. MRI of brain iron. AJR. 147:1986;103-110.
20. Ryvlin P., Broussolle E., Piollet H., Viallet F., Khalfallah Y., Chazot G. Magnetic resonance imaging evidence of decreased putamenal iron content in idiopathic Parkinson's disease. Arch Neurol. 52:1995;583-588.
21. Antonini A., Leenders K.L., Meier D., Oertel W.H., Boesiger P., Anliker M. T2 relaxation time in patients with Parkinson's disease. Neurology. 43:1993;697-700.
22. Gorell J.M., Ordidge R.J., Brown G.G., Deniau J.C., Buderer N.M., Helpern J.A. Increased iron-related MRI contrast in the substantia nigra in Parkinson's disease. Neurology. 45:1995;1138-1143. [published erratum appears in Neurology 1995 Jul;45(7):1420].
23. Bartzokis G., Aravagiri M., Oldendorf W.H., Mintz J., Marder S.R. Field dependent transverse relaxation rate increase may be a specific measure of tissue iron stores. Magn Reson Med. 29:1993;459-464.
24. Bartzokis G., Mintz J., Sultzer D., Marx P., Herzberg J.S., Phelan C.K., Marder S.R. In vivo MR evaluation of age-related increases in brain iron. AJNR. 15:1994;1129-1138.
25. Bartzokis G., Sultzer D., Mintz J., Holt L.E., Marx P., Phelan C.K., Marder S.R. In vivo evaluation of brain iron in Alzheimer's disease and normal subjects using MRI. Biol Psych. 35:1994;480-487.
26. Bartzokis G., Beckson M., Hance D.B., Marx P., Foster J.A., Marder S.R. MR evaluation of age-related increase of brain iron in young adult and older normal males. Magn Reson Imag. 15:1997;29-35.
27. Vymazal J., Hajek M., Patronas N., Giedd J.N., Bulte J.W., Baumgarner C., Tran V., Brooks R.A. The quantitative relation between T1-weighted and T2-weighted MRI of normal gray matter and iron concentration. J Magn Reson Imag. 5:1995;554-560.
28. Vymazal J., Brooks R.A., Baumgarner C., Tran V., Katz D., Bulte J.W., Bauminger R., Di Chiro G. The relation between brain iron and NMR relaxation times An in vitro study . Magn Reson Med. 35:1996;56-61.
29. Vymazal J., Zak O., Bulte J.W., Aisen P., Brooks R.A. T1 and T2 of ferritin solutions: Effect of loading factor. Magn Reson Med. 36:1996;61-65.
30. Vymazal J., Brooks R.A., Patronas N., Hajek M., Bulte J.W., Di Chiro G. Magnetic resonance imaging of brain iron in health and disease. J Neurol Sci. 134:(Suppl.):1995;19-26.
31. Bulte J.W., Miller G.F., Vymazal J., Brooks R.A., Frank J.A. Hepatic hemosiderosis in non-human primates quantification of liver iron using different field strengths . Magn Reson Med. 37:1997;530-536.
32. Wu R.M., Chiu H.C., Wang M., Chen R.C. Risk factors on the occurrence of response fluctuations and dyskinesias in Parkinson's disease. J Neural Transm Park Dis Dement Sect. 5:1993;127-133.
33. Kostic V., Przedborski S., Flaster E., Sternic N. Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease. Neurology. 41:1991;202-205.
34. Golbe L.I. Young-onset Parkinson's disease A clinical review . Neurology. 41:1991;168-173.
35. Wagner M.L., Fedak M.N., Sage J.I., Mark M.H. Complications of disease and therapy A comparison of younger and older patients with Parkinson's disease . Ann Clin Lab Sci. 26:1996;389-395.
36. Pantelatos A., Fornadi F. Clinical features and medical treatment of Parkinson's disease in patient groups selected in accordance with age at onset. Adv Neurol. 60:1993;690-697.
37. Friedman A. Old-onset Parkinson's disease compared with young-onset disease Clinical differences and similarities . Acta Neurol Scand. 89:1994;258-261.
38. Kostic V.S., Filipovic S.R., Lecic D., Momcilovic D., Sokic D., Sternic N. Effect of age at onset on frequency of depression in Parkinson's disease. J Neurol Neurosurg Psych. 57:1994;1265-1267.
39. Mayeux R., Marder K., Cote L.J., Denaro J., Hemenegildo N., Mejia H., Tang M.X., Lantigua R., Wilder D., Gurland B. The frequency of idiopathic Parkinson's disease by age, ethnic group, and sex in northern Manhattan, 1988-1993. Am J Epidemiol. 142:1995;820-827. [see comments].
40. Mutch W.J., Dingwall-Fordyce I., Downie A.W., Paterson J.G., Roy S.K. Parkinson's disease in a Scottish city. Br Med J (Clin Res Ed). 292:1986;534-536.
41. Marttila R.J., Rinne U.K. Epidemiology of Parkinson's disease in Finland. Acta Neurol Scand. 53:1976;81-102.
42. Morgante L., Rocca W.A., Di Rosa A.E., De Domenico P., Grigoletto F., Meneghini F., Reggio A., Savettieri G., Castiglione M.G., Patti F. Prevalence of Parkinson's disease and other types of parkinsonism A door-to-door survey in three Sicilian municipalities . The Sicilian Neuro-Epidemiologic Study (SNES) Group. Neurology. 42:1992;1901-1907.
43. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., Di Iorio G., Golbe L.I., Nussbaum R.L. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science (Washington DC). 276:1997;2045-2047. [see comments].
44. Hughes A.J., Daniel S.E., Kilford L., Lees A.J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease A clinico-pathological study of 100 cases . J Neurol Neurosurg Psychiatry. 55:1992;181-184. [see comments].
45. Montgomery G.K. PD and the Columbia Scale. Neurology. 34:1984;557-558. [letter].
46. Folstein M.F., Folstein S.E., McHugh P.R. "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 12:1975;189-198.
47. Naidich T.P., Daniels D.L., Pech P., Haughton V.M., Williams A., Pojunas K. Anterior commissure Anatomic-MR correlation and use as a landmark in three orthogonal planes . Radiology. 158:1986;421-429.
48. Morris C.M., Candy J.M., Oakley A.E., Bloxham C.A., Edwardson J.A. Histochemical distribution of non-haem iron in the human brain. Acta Anat (Basel). 144:1992;235-257.
49. Dexter D.T., Sian J., Jenner P., Marsden C.D. Implications of alterations in trace element levels in brain in Parkinson's disease and other neurological disorders affecting the basal ganglia. Narabayashi H., Nagatsu T., Yanagisawa N., Mizuno Y. Advances in Neurology. Vol. 60:1993;273-281 Raven Press, New York.
50. Brooks D.J., Luthert P., Gadian D., Marsden C.D. Does signal-attenuation on high-field T2-weighted MRI of the brain reflect regional cerebral iron deposition? Observations on the relationship between regional cerebral water proton T2 values and iron levels. J Neurol Neurosurg Psych. 52:1989;108-111.
51. Drayer B.P. Basal ganglia Significance of signal hypointensity on T2-weighted MR images . Radiology. 173:1989;311-312. [editorial].
52. Kucharczyk W., Henkelman R.M., Chen J. Brain iron and T2 signal. AJNR. 15:1994;1795-1796. [letter; comment].
53. Malisch T.W., Hedlund L.W., Suddarth S.A., Johnson G.A. MR microscopy at 7.0 T Effects of brain iron . J Magn Reson Imag. 1:1991;301-305.
54. Schenker C., Meier D., Wichmann W., Boesiger P., Valavanis A. Age distribution and iron dependency of the T2 relaxation time in the globus pallidus and putamen. Neuroradiology. 35:1993;119-124.
55. Kamman R.L., Go K.G., Brouwer W., Berendsen H.J. Nuclear magnetic resonance relaxation in experimental brain edema Effects of water concentration, protein concentration, and temperature . Magn Reson Med. 6:1988;265-274.
56. Fearnley J.M., Lees A.J. Aging and Parkinson's disease Substantia nigra regional selectivity . Brain. 114:1991;2283-2301.
57. McRitchie H.A., Halliday G.M., Cartwright H., Hely M.A., Morris J.G.L. Pattern of midbrain pathology in different parkinsonian syndromes. Ohye C., Kimura M., McKenzie J.S. The Basal Ganglia V (series title: Advances in behavioral biology, v. 47). 1996;441-444 Plenum Press, New York.
58. Young I.R., Payne J.A., Bryant D.J., Bailes D.R., Hall A.S., Bydder G.M. Artifacts in the measurement of T1 and T2. Partain C.L., Price R.R., Patton J.A., Kulkarni M.V., James A.E. Magnetic Resonance Imaging. 2nd ed. 1988;1321-1334 Saunders, Philadelphia.
59. Darwin R.H., Drayer B.P., Riederer S.J., Wang H.Z., MacFall J.R. T2 estimates in healthy and diseased brain tissue A comparison using various MR pulse sequences . Radiology. 160:1986;375-381.
60. Jones J.P. T1 and T2 measurement. Partain C.L., Price R.R., Patton J.A., Kulkarni M.V., James A.E. Magnetic Resonance Imaging. 2nd ed. 1988;1311-1320 Saunders, Philadelphia.
61. Custer E.M., Finch C.A., Sobel R.E., Zettner A. Population norms for serum ferritin. J Lab Clin Med. 126:1995;88-94.
62. de Rijk M.C., Tzourio C., Breteler M.M., Dartigues J.F., Amaducci L., Lopez-Pousa S., Manubens-Bertran J.M., Alperovitch A., Rocca W.A. Prevalence of parkinsonism and Parkinson's disease in Europe: The EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease. J Neurol Neurosurg Psychiatry. 62:1997;10-15.
63. Halliwell B., Gutteridge J.M. The importance of free radicals and catalytic metal ions in human diseases. Mol Aspects Med. 8:1985;89-193.
64. Halliwell B., Gutteridge J.M.C. Iron as biologic pro-oxidant. ISI Atlas Sci Biochem. 1:1988;48-52.